Uniphar PLC Notice of AGM & Annual Report & Dividend Update (5254V)

TIDMUPR

RNS Number : 5254V

Uniphar PLC

06 April 2023

Publication of Notice of Annual General Meeting and Annual Report and Dividend Update

Dublin, London | 6 April 2023: Uniphar plc (the "Company" or "Uniphar") wishes to announce that it is today posting to shareholders its Notice of Annual General Meeting ("AGM") for 2023 together with its annual report and accounts for the year ended 31 December 2022 ("Annual Report"). The AGM will be held at 11.00 a.m. on 11 May 2023 at the offices of William Fry LLP, 2 Grand Canal Square, Dublin 2, D02 A342.

Uniphar values the participation of its shareholders at its AGM and encourages all shareholders to take part in the meeting either in person or by voting and raising questions in advance.

The Notice of Meeting, Form of Proxy, Annual Report and accounts are available to view on the Company's website at https://www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2023/ and will be available for inspection during normal business hours on any business day from today until the conclusion of the AGM at the registered office of the Company.

Proxy voting can be carried out in advance of the AGM. Details of how to do so are set out in further detail in the Notice of Meeting.

A conference call facility will be provided to allow shareholders to listen live to the business of the AGM. Please note that you will not be able to use this facility to vote, raise points or issues or ask questions. If you wish to listen live to the AGM proceedings, you can register for the conference call and receive participant log-in detailsat https://www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2023/ . Shareholders availing of this facility should ensure to submit any votes in advance of the meeting as it will not be possible to vote using the conference call facility.

Shareholders are invited to submit questions in writing in advance of the meeting either by email to [e-mail] or by post to the Company Secretary, Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co. Dublin, D24 V06K, Ireland. Questions must be received by 11.00 a.m. on 9 May 2023 . Shareholders must include their Shareholder Reference Number (as set out on their Form of Proxy) with any question submitted.

Dividend Update

This announcement also amends the final dividend amount per share for approval at the AGM to EUR0.0113 per ordinary share, from EUR0.011 per ordinary share as published in the 2022 preliminary results released on 28 February 2023.

For further details contact:

 
Uniphar Group                                      Tel: [phone] 
Allan Smylie, Head of Strategy and IR 
 
Davy (Joint Corporate Broker, Nominated Advisor    Tel: [phone] 
 and 
 Euronext Growth Listing Sponsor) 
Barry Murphy 
 Niall Gilchrist 
 
RBC Capital Markets (Joint Corporate Broker)       Tel: [phone] 
                                                    4000 
Jonathan Hardy 
 Jamil Miah 
 
Stifel Nicolaus Europe Limited (Joint Corporate    Tel: + 44 (0) 20 7710 
 Broker)                                            7600 
Matt Blawat 
 Ben Maddison 
 Francis North 
 
Q4 PR                                              Tel: [phone] 
Iarla Mongey, Public Relations Advisor to Uniphar 
 Group 
 

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers. Active in Ireland, the UK, Benelux, the Nordics, Germany and the US, the Group is growing with its clients to provide pan-European solutions, with a targeted service offering in the US. Uniphar has built fully integrated digitally enabled customer centric solutions that are supported by our highly experienced and clinically trained teams, leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On Demand", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in the wholesale/hospital market, supported by a network of 423 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are also utilised for the benefit of the Commercial & Clinical and Product Access divisions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUPUGUCUPWGCA

(END) Dow Jones Newswires

April 06, 2023 02:00 ET (06:00 GMT)